

### AMENDMENT

Please Amend the Specification by replacing the previous Sequence Listing with the Sequence Listing enclosed herewith.


### REMARKS

In response to the "Notice to Comply with Sequence Listing Requirements" please find the following enclosed herewith: 1) a substitute Sequence Listing in both paper and computer readable formats; 2) the statement required under 37 C.F.R. §§ 1.825(a) and (b) and 1.821(g); and the required copy of the "NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES."

In addition to correcting the errors noted in the "NOTICE", the Sequence Listing has been corrected by replacing the abbreviation, "Cit" with the full term "citrulline," as it is used in the specification as originally filed (*see*, for example, page 3, line 20 of the Specification).

The Examiner is invited to contact the undersigned patent agent at (713) 787-1589 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Matthew L. Madsen  
Reg. No. 45,594  
Agent for Assignee  
INNOGENETICS N.V.

HOWREY SIMON ARNOLD & WHITE, LLP  
750 Bering Drive  
Houston, Texas 77057-2198  
(713) 787-1400

Date: January 18, 2002